Gulf Coast Consortia

QUANTITATIVE BIOMEDICAL SCIENCES

Houston Biotech Showcase

August 19, 2022

Fannin Innovation Studio

Amanda Gibbens

Elise Waldron

Institute for Applied Cancer Science (IACS)

Edith Nagy (PhD) and Lisa Mustachio (PhD)

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

IACS - SMALL MOLECULE DRUG DISCOVERY GROUP

PART OF MD ANDERSON'S THERAPEUTICS DISCOVERY AND DEVELOPMENT DIVISION

- IACS started in 2012 as part of MD Anderson's goal of establishing its own internal therapeutics discovery and development unit.
- Singular mission: **Develop Impactful Therapies**.
- Over 10 years, several compounds have been licensed to partners and taken into the clinic:
  - IACS-10759 - OXPHOS
  - IPN-60090 - GLS
  - BBP-398 - SHP2
  - ART-0380 - ATR
- Current pipeline includes multiple projects focused on cancer and CNS indications.



Edith Nagy, PhD – Research Scientist

enagy@mdanderson.org

https://www.linkedin.com/in/edith-nagy/

Started at IACS: **February 2019**

Post-Doc: **Boston University (2017-2018)**

PhD: **Florida Atlantic University (2012-2017)**

Current role: **Project lead – Medicinal Chemistry**

Responsibilities:

- **Manage internal/external resources (chemistry team and direct reports).**
- **Work with cross-functional team members to ensure project direction and progress.**
- **Design, synthesize molecules and data analysis.**
- **Job breakdown: 40% in lab, 30% managing med chem team, 30% in project related meetings.**

Lisa Mustachio, PhD – Research Investigator

lmustachio@mdanderson.org

https://www.linkedin.com/in/lisamariamustachio

Started at IACS: **February 2020**

Post-Doc: **MD Anderson Cancer Center (2017-2021)**

PhD: **Dartmouth College (2011-2016)**

Current role: **Project lead – In Vitro Pharmacology**

Responsibilities:

- **Ensure the project team makes sound, data-driven decisions.**
- **Optimize and perform assays in the drug screening funnel to uncover lead compounds.**
- **Design biology experiments to answer key questions.**
- **Job breakdown: 70% in lab, 30% in project related meetings.**

Next challenge: **Deliver *in vivo* PoC for current project**

For job openings, please visit: https://jobs.mdanderson.org/search/searchjobs Keyword: **IACS**

Postdoctoral position openings: Please contact us.

Hope Biosciences

Hosu Kim Christopher Lewis Nader Lotfi

Hummingbird Bioscience

Developing Precision Therapies Against Hard-to-Drug Targets

August 2022 | Leah DiMascio, Chief Development Officer

Our Approach | Data science and systems biology underpin our ability to discover and develop potential important new drugs

RIGHT TARGET

Data-driven systems biology helps us identify and validate clinically relevant targets

- Our state-of-the-art computational analysis of patient data sets allows us to identify clinically relevant targets
- Our rigorous systems approach helps us to validate the clinical opportunity and identify predictive biomarkers

RIGHT MOLECULE

Computational biology & machine learning enables design of precision biologics

- **mAbPredict** protein structure prediction, epitope modeling, and selection help identify key epitopes to target
- **mAbHits** platform enables engineering of specific antibodies against key functional epitopes

RIGHT PATIENTS

Data analysis and deep clinical expertise allows us to design precision clinical trials

- Mechanistic and patient data help us design relevant disease models and inform our biomarker-based strategy
- Our world class clinical team intends to leverage biomarkers to design faster & more effective clinical trials.

Open Positions

- Director, Biostatistics
- Research Scientist, Pharmacokinetics
- Research Scientist, Bioconjugation
- Internship, Structural Bioinformatics
- Internship, Genomics

Ridgeline Therapeutics

Stan Watowich

Salarius PHARMACEUTICALS

August 19, 2022

Tremaine Brown, CCRP – Clinical Team Lead

Aundrietta Duncan, PhD – Director, Non-clinical Development

Annie Yan, CPA – Corporate Controller

Salarius PHARMACEUTICALS

An emerging biotech developing targeted therapies to treat pediatric and other cancers, including advanced solid tumors.



[1] Topotecan and cyclophosphamide [2] Investigator initiated trial active at MD Anderson Cancer Center treating patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia [3] Investigator initiated trial – Clinical trial agreement not yet finalized.

Salarius Organization



TMC Innovation

Ahmed AlRawi